News

Investigators reflect on the Oncology Care Model and its implications.

The median overall survival with niraparib, abiraterone acetate, and prednisone was 30.4 months vs 28.6 months with abiraterone acetate and prednisone alone.

The duration of response was 39.2 months among patients with 1 metastatic site treated in the combination arm vs 29.5 months for patients given sunitinib.

Adjuvant pembrolizumab improved overall survival vs placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence.

The 3-year progression-free survival rate was 94% and the 3-year overall survival rate was 97%.

As with all patients with cancer, providing care for those with lung cancer involves both physiological and psychological aspects.

The median progression-free survival with cabozantinib was 8.3 months vs 3.2 months with placebo among patients with extra-pancreatic neuroendocrine tumors.

Freshta Poupal, RN, and Frannie Bell, NP, share their experiences with teclistamab in clinical practice.

A lung cancer screening navigator offers their perspective on shared decision-making.

An initiative led by nurses helped reduce operating-room pressure injuries and saved their institution an estimated $80,210 per year.

The FDA has approved pembrolizumab in combination with chemotherapy as a treatment for patients with locally advanced unresectable or metastatic biliary tract cancer.

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

The Oncology Care Model did not significantly improve care, yet patients were satisfied with their care and many oncologists overcame their hesitancy towards value-based models.

The FDA has approved toripalimab, with cisplatin and gemcitabine, and as a monotherapy, to treat adults with nasopharyngeal carcinoma.

Patients who received amivantamab plus lazertinib and chemotherapy achieved a median progression-free survival of 8.3 months.

The median progression-free survival was not reached with atezolizumab plus chemotherapy vs 6.9 months in the placebo group of patients with advanced or recurrent endometrial cancer.

Amanda Smith, a registered nurse with Huntsman Cancer Institute, discusses the impact that early satiety can have on patients with myeloproliferative neoplasms and the role nurses play in helping patients manage this symptom.

The median progression-free survival was 23.7 months with the combination vs 16.6 months with osimertinib alone.

The median radiologic progression-free survival was 12.02 months in the 177Lu-PSMA-617 group vs 5.59 months in the androgen receptor pathway inhibitor change group.

Datopotamab deruxtecan improved progression-free survival in select subsets of patients with advanced or metastatic non–small-cell lung cancer.

Patients with metastatic hormone receptor-positive breast cancer treated with datopotamab deruxtecan experienced a statistically significant and clinically meaningful improvement in progression-free survival.

Ivosidenib, a targeted therapy, has been approved for patients with relapsed or refractory myelodysplastic syndromes and an IDH1 mutation.

Sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer.

The 12-month overall survival rates were 48.7% and 35.3% with tisotumab vedotin and chemotherapy, respectively, among patients with recurrent or metastatic cervical cancer.

Patients who received induction chemotherapy prior to chemoradiation had a 35% reduced risk of progression or death.

Nivolumab plus gemcitabine-cisplatin improved overall and progression-free survival in unresectable or metastatic urothelial carcinoma.

For the first time, a new therapeutic regimen outperformed chemotherapy in improving overall survival in frontline urothelial cancer.

Durvalumab plus first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib, emerges as a potentially effective combination for patients with limited treatment options.

Amivantamab plus chemotherapy nearly doubled the progression-free survival in patients with EGFR Exon 20-mutated non–small-cell lung cancer.

In the intention-to-treat population, the median progression-free survival was 24.8 months with selpercatinib vs 11.2 months.